In a bid to enhance access to affordable healthcare, a bipartisan group of U.S. senators has reintroduced legislation targeting the regulatory processes surrounding biosimilars. The proposed amendment seeks to redefine the criteria for determining when biosimilars—cheaper, near-identical versions of biologic drugs—are considered interchangeable with their branded counterparts.
This legislative move aims to lower the barriers that currently limit the availability of cost-effective biologic alternatives, potentially easing financial burdens for patients requiring such treatments. The senators argue that the current framework inhibits market competition and keeps drug prices high.
For further details on this legislative effort, the original article is available at Law360.